{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T08:10:05Z","timestamp":1755936605671,"version":"3.44.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pierre Fabre Pharma AG"},{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Iron deficiency (ID) often leads to iron deficiency anemia (IDA). Oral iron supplements are frequently associated with gastrointestinal intolerance and poor adherence. Ferric derisomaltose (FDI), a single high-dose intravenous (IV) infusion, is another option. The real-world Real-CHOICE study investigated the attitudes of patients with IDA and ID without anemia (IDNA) towards IV iron therapy. Secondary objectives were the effectiveness and safety of FDI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Real-CHOICE (NCT04318405) enrolled adults with IDA or IDNA in Switzerland. Custom questionnaires evaluated attitudes and treatment satisfaction at baseline and follow-up (\u2265\u200912\u00a0weeks). Hemoglobin, ferritin, and transferrin saturation levels, and treatment-emergent adverse events (TEAEs) were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 319 patients (114 with IDA, 205 with IDNA) who received FDI, most were female (n\u2009=\u2009305, 93.9%) and aged\u2009&lt;\u200965\u00a0years (n\u2009=\u2009298, 91.7%). Over three-quarters of patients were not hesitant to receive IV iron treatment at baseline (n\u2009=\u2009228, 76.3%) and follow-up (n\u2009=\u2009194, 78.2%). The proportion of patients whose attitude towards receiving IV iron therapy remained stable or improved at follow-up versus baseline was 86.1% (n\u2009=\u2009204\/237). Of 195 patients with available data, mean (standard deviation) changes from baseline to follow-up in hemoglobin, ferritin, and transferrin saturation levels were 1.15 (1.50) g\/dL, 144.87 (131.77) \u00b5g\/L, and 8.71% (13.29%), respectively. TEAEs and adverse drug reactions occurred in 76 (23.8%) and 22 patients (6.9%), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Real-CHOICE revealed favorable attitudes of patients and physicians towards IV iron therapies, particularly FDI, in a real-world setting. Improved hematologic parameters and favorable safety highlight FDI\u2019s potential as a clinically effective treatment for ID and IDA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00404-025-08085-5","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:54:49Z","timestamp":1750431289000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes towards ferric derisomaltose among Swiss patients with iron deficiency and their treating physicians: the prospective, observational Real-CHOICE study"],"prefix":"10.1007","volume":"312","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-1552","authenticated-orcid":false,"given":"Petra","family":"Stute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Alexandre","family":"Krayenb\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan R.","family":"Vavricka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"8085_CR1","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1016\/S2352-3026(23)00160-6","volume":"10","author":"GBD","year":"2021","unstructured":"GBD (2021) Anaemia Collaborators (2023) Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990\u20132021: findings from the Global Burden of Disease Study 2021. Lancet Haematol 10:e713\u2013e734. https:\/\/doi.org\/10.1016\/S2352-3026(23)00160-6","journal-title":"Lancet Haematol"},{"key":"8085_CR2","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3945\/ajcn.114.103366","volume":"102","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Williet N, Cacoub P (2015) Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr 102:1585\u20131594. https:\/\/doi.org\/10.3945\/ajcn.114.103366","journal-title":"Am J Clin Nutr"},{"key":"8085_CR3","doi-asserted-by":"publisher","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","volume":"10","author":"Z Tolkien","year":"2015","unstructured":"Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ (2015) Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS ONE 10:e0117383. https:\/\/doi.org\/10.1371\/journal.pone.0117383","journal-title":"PLoS ONE"},{"key":"8085_CR4","doi-asserted-by":"publisher","first-page":"e000759","DOI":"10.1136\/bmjgast-2021-000759","volume":"9","author":"A Kumar","year":"2022","unstructured":"Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ (2022) Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol 9:e000759. https:\/\/doi.org\/10.1136\/bmjgast-2021-000759","journal-title":"BMJ Open Gastroenterol"},{"key":"8085_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","volume":"20","author":"I Blumenstein","year":"2021","unstructured":"Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W (2021) Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf 20:757\u2013769. https:\/\/doi.org\/10.1080\/14740338.2021.1912010","journal-title":"Expert Opin Drug Saf"},{"key":"8085_CR6","unstructured":"Pierre Fabre Pharma AG (2023) MonoFer: summary of product characteristics (SmPC). https:\/\/www.swissmedicinfo.ch\/. Accessed 12 May 2025"},{"key":"8085_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/vox.12475","volume":"112","author":"C Holm","year":"2017","unstructured":"Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J (2017) Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang 112:122\u2013131. https:\/\/doi.org\/10.1111\/vox.12475","journal-title":"Vox Sang"},{"key":"8085_CR8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00404-022-06768-x","volume":"308","author":"R Hansen","year":"2023","unstructured":"Hansen R, Sommer VM, Pinborg A, Krebs L, Thomsen LL, Moos T, Holm C (2023) Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. Arch Gynecol Obstet 308:1165\u20131173. https:\/\/doi.org\/10.1007\/s00404-022-06768-x","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"8085_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/ajg.2013.335","volume":"108","author":"W Reinisch","year":"2013","unstructured":"Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL (2013) A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 108(12):1877\u20131888. https:\/\/doi.org\/10.1038\/ajg.2013.335","journal-title":"Am J Gastroenterol"},{"key":"8085_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ajh.25564","volume":"94","author":"M Auerbach","year":"2019","unstructured":"Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J (2019) A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol 94:1007\u20131014. https:\/\/doi.org\/10.1002\/ajh.25564","journal-title":"Am J Hematol"},{"issue":"1","key":"8085_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","volume":"36","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M (2021) Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant 36(1):111\u2013120. https:\/\/doi.org\/10.1093\/ndt\/gfaa011","journal-title":"Nephrol Dial Transplant"},{"key":"8085_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, Reinisch W, Iqbal T (2023) Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut 72:644\u2013653. https:\/\/doi.org\/10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"issue":"5","key":"8085_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H (2020) Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA 323(5):432\u2013443. https:\/\/doi.org\/10.1001\/jama.2019.22450","journal-title":"JAMA"},{"key":"8085_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/17474086.2021.1858406","volume":"14","author":"X Kassianides","year":"2021","unstructured":"Kassianides X, Bodington R, Bhandari S (2021) An evaluation of ferric derisomaltose as a treatment for anemia. Expert Rev Hematol 14:7\u201329. https:\/\/doi.org\/10.1080\/17474086.2021.1858406","journal-title":"Expert Rev Hematol"},{"key":"8085_CR15","doi-asserted-by":"publisher","first-page":"18401","DOI":"10.1038\/s41598-023-44578-6","volume":"13","author":"X Kassianides","year":"2023","unstructured":"Kassianides X, Bhandari S (2023) Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD. Sci Rep 13:18401. https:\/\/doi.org\/10.1038\/s41598-023-44578-6","journal-title":"Sci Rep"},{"key":"8085_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW (2016) A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 31:646\u2013655. https:\/\/doi.org\/10.1093\/ndt\/gfv293","journal-title":"Nephrol Dial Transplant"},{"key":"8085_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12882-020-02180-2","volume":"21","author":"PA Kalra","year":"2020","unstructured":"Kalra PA, Bhandari S, Spyridon M, Davison R, Lawman S, Mikhail A, Reaich D, Pritchard N, McCafferty K, Moore J (2020) NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol 21:539. https:\/\/doi.org\/10.1186\/s12882-020-02180-2","journal-title":"BMC Nephrol"},{"key":"8085_CR18","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1080\/14767058.2018.1449205","volume":"32","author":"C Holm","year":"2019","unstructured":"Holm C, Thomsen LL, Langhoff-Roos J (2019) Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med 32:2797\u20132804. https:\/\/doi.org\/10.1080\/14767058.2018.1449205","journal-title":"J Matern Fetal Neonatal Med"},{"key":"8085_CR19","doi-asserted-by":"publisher","first-page":"4585164","DOI":"10.1155\/2017\/4585164","volume":"2017","author":"SO Frigstad","year":"2017","unstructured":"Frigstad SO, Haaber A, Bajor A, Fallingborg J, Hammarlund P, Bonderup OK, Blom H, Rannem T, Hellstr\u00f6m PM (2017) The NIMO Scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract 2017:4585164. https:\/\/doi.org\/10.1155\/2017\/4585164","journal-title":"Gastroenterol Res Pract"},{"key":"8085_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5414\/cn109474","volume":"91","author":"G Jensen","year":"2019","unstructured":"Jensen G, G\u00f8ransson LG, Fernstr\u00f6m A, Furuland H, Christensen JH (2019) Treatment of iron deficiency in patients with chronic kidney disease: a prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol 91:246\u2013253. https:\/\/doi.org\/10.5414\/cn109474","journal-title":"Clin Nephrol"},{"key":"8085_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/flgastro-2020-101406","volume":"12","author":"J Kearns","year":"2021","unstructured":"Kearns J, Jacob SG (2021) Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders. Frontline Gastroenterol 12:265\u2013271. https:\/\/doi.org\/10.1136\/flgastro-2020-101406","journal-title":"Frontline Gastroenterol"},{"key":"8085_CR22","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","volume":"154","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H (2022) Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone 154:116202. https:\/\/doi.org\/10.1016\/j.bone.2021.116202","journal-title":"Bone"},{"key":"8085_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H (2021) Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol 87:2256\u20132273. https:\/\/doi.org\/10.1111\/bcp.14643","journal-title":"Br J Clin Pharmacol"},{"key":"8085_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","volume":"45","author":"NA Kennedy","year":"2023","unstructured":"Kennedy NA, Achebe MM, Biggar P, P\u00f6hlmann J, Pollock RF (2023) A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm 45:604\u2013612. https:\/\/doi.org\/10.1007\/s11096-023-01548-2","journal-title":"Int J Clin Pharm"},{"key":"8085_CR25","doi-asserted-by":"publisher","first-page":"18859","DOI":"10.1038\/s41598-022-23581-3","volume":"12","author":"RCF Sinclair","year":"2022","unstructured":"Sinclair RCF, Nadaraja S, Kennedy NA, Wakatsuki M, Bhandari S (2022) Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK. Sci Rep 12:18859. https:\/\/doi.org\/10.1038\/s41598-022-23581-3","journal-title":"Sci Rep"},{"issue":"7","key":"8085_CR26","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ajh.27220","volume":"99","author":"L Van Doren","year":"2024","unstructured":"Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M (2024) Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions. Am J Hematol 99(7):1338\u20131348. https:\/\/doi.org\/10.1002\/ajh.27220","journal-title":"Am J Hematol"},{"issue":"11","key":"8085_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G (2014) Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99(11):1671\u20131676. https:\/\/doi.org\/10.3324\/haematol.2014.111492","journal-title":"Haematologica"},{"key":"8085_CR28","unstructured":"Vifor (International) Inc. (2022) Ferinject: Summary of Product Characteristics. https:\/\/www.swissmedicinfo.ch\/. Accessed 2 May 2025"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-025-08085-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T07:53:10Z","timestamp":1755935590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-025-08085-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["8085"],"URL":"https:\/\/doi.org\/10.1007\/s00404-025-08085-5","relation":{},"ISSN":["1432-0711"],"issn-type":[{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Petra Stute received honoraria for speaking engagements from Besins Healthcare, Exeltis, Jenapharm, Bayer, Drossapharm, Theramex, Gedeon-Richter, Viatris, Astellas, Effik, Hexal, Labatec, Pierre Fabre, Pharmacosmos, Vifor, Zeller, and Schaer Pharma, and served as a consultant for Theramex, Astellas, Pharmacosmos, and Bionorica. Pierre-Alexandre Krayenb\u00fchl received consulting fees from Pierre Fabre and Vifor Pharma. Stephan R. Vavricka has received consulting fees, speaker honoraria, and unrestricted research grants from Abbott, Alfasigma, Amgen, Arenapharm, BMS, Falk Pharma GmbH, Ferring Pharmaceuticals, Gilead, iQuone, Janssen, MSD, Permamed, Pfizer Inc., Pharmacosmos, Pierre Fabre, Sanofi-Aventis, Schwabe Pharma, Takeda, Tillotts, UCB, and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice as prescribed by Swissmedic and the European Medicines Agency criteria for non-interventional studies, and approved by the Kantonale Ethikkommission Zurich (BASEC-No. 2020\u201300119, 26 March 2020). The study was registered on ClinicalTrials.gov (NCT04318405). The data were anonymized upon completion of the analyses, except for pharmacovigilance data, which were processed on a pseudonymous basis due to legal requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent before inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}